Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 16:13:1221096.
doi: 10.3389/fonc.2023.1221096. eCollection 2023.

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

Alberto Farolfi  1 , Elisabetta Petracci  2 , Giorgia Gurioli  3 , Gianluca Tedaldi  3 , Claudia Casanova  4 , Valentina Arcangeli  5 , Andrea Amadori  6 , Marta Rosati  7 , Marco Stefanetti  8 , Salvatore Luca Burgio  1 , Maria Concetta Cursano  1 , Cristian Lolli  1 , Valentina Zampiga  3 , Ilaria Cangini  3 , Giuseppe Schepisi  1 , Ugo De Giorgi  1
Affiliations

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

Alberto Farolfi et al. Front Oncol. .

Abstract

Introduction: Primary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC) could influence patient outcomes.

Methods: We conducted a multicenter retrospective cohort study of advanced (International Federation of Gynecology and Obstetrics (FIGO) stage III or IV) OC treated between 2014 and 2018 to assess progression-free survival (PFS) and overall survival (OS) in relation to TTC. All patients underwent a germline multigene panel for BRCA1/2 evaluation.

Results: Among the 83 patients who underwent PDS, a TTC ≥ 60 days was associated with a shorter PFS (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.04-3.93, p = 0.038), although this association lost statistical significance when adjusting for residual disease (HR 1.52, 95% CI 0.75-3.06, p = 0.244, for TTC and HR 2.73, 95% CI 1.50-4.96, p = 0.001, for residual disease). Among 52 IDS patients, we found no evidence of an association between TTC and clinical outcomes. Ascites, type of chemotherapy, or germline BRCA1/2 mutational status did not influence TTC and were not associated with clinical outcomes in PDS or IDS patients.

Discussion: In conclusion, longer TTC seems to negatively affect prognosis in patients undergoing PDS, especially those with residual disease.

Keywords: BRCA1/2 mutation; interval debulking surgery; ovarian cancer prognosis; primary debulking surgery; residual disease; time to initiation of chemotherapy.

PubMed Disclaimer

Conflict of interest statement

UG has received advisory board or consultancy fees from Merck Sharp & Dohme, Bristol Myers Squibb, Janssen, Astellas, Sanofi, Bayer, Pfizer, Ipsen, Novartis, and Pharmamar and institutional research grants from AstraZeneca, Sanofi, and Roche. AF has received personal honoraria for lectures from AstraZeneca, GSK-Tesaro, and Clovis and is on the advisory board of Janssen, AstraZeneca, and GSK-Tesaro. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of patients included in the analysis.
Figure 2
Figure 2
Kaplan–Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) according to time to initiation of adjuvant chemotherapy (TTC) in patients undergoing primary debulking surgery.
Figure 3
Figure 3
Kaplan–Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) according to time to initiation of adjuvant chemotherapy (TTC) in patients undergoing interval debulking surgery.
See this image and copyright information in PMC

References

    1. Cannistra SA. Cancer of the ovary. N Engl J Med (2004) 351:2519–29. doi: 10.1056/NEJMra041842 - DOI - PubMed
    1. Colombo N, Ledermann JA, ESMO Guidelines Committee . Electronic address: clinicalguidelines@esmo.org. Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. Ann Oncol (2021) 32:1300–3. doi: 10.1016/j.annonc.2021.07.004 - DOI - PubMed
    1. Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer (2020) 30:1657–64. - PubMed
    1. Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer (2019) 2019:ijgc–2019-000308. doi: 10.1136/ijgc-2019-000308 - DOI - PubMed
    1. Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 25:3621–7. doi: 10.1200/JCO.2006.10.2517 - DOI - PubMed